Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2014011104
pages 531-557

Gastroretentive Drug Delivery Systems for Therapeutic Management of Peptic Ulcer

Tarun Garg
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India
Animesh Kumar
M. Pharm
Goutam Rath
Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India; Punjab Technical University, Kapurthala, Punjab, India
Amit Kumar Goyal
Department of Pharmaceutics, ISF College of Pharmacy, Moga (Punjab), India; Punjab Technical University, Kapurthala, Punjab, India

RESUMO

A peptic ulcer, stomach ulcer, or gastric ulcer, also known as peptic ulcer disease (PUD), is a very common chronic disorder of the stomach which is mainly caused by damage or impairment of the stomach lining. Various factors such as pepsin, gastric acid, H. pylori, NSAIDs, prostaglandins, mucus, bicarbonate, and blood flow to mucosa play an important role in causing peptic ulcers. In this review article, our main focus is on some important gastroretentive drug delivery systems (GRDDS) (floating, bioadhesive, high density, swellable, raft forming, superporous hydrogel, and magnetic systems) which will be helpful in gastroretention of different dosage forms for treatment of peptic ulcer. GRDDS provides a mean for controlled release of compounds that are absorbed by active transport in the upper intestine. It also enables controlled delivery for paracellularly absorbed drugs without a decrease in bioavailability. The above approaches are specific for targeting and leading to a marked improvement in the quality of life for a large number of patients. In the future, it is expected that they will become of growing significance, finally leading to improved efficiencies of various types of pharmacotherapies.


Articles with similar content:

Mucoadhesion and the Gastrointestinal Tract
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 3
Joao J. S. Sousa, Abdul W. Basit, Emma L. McConnell, Felipe J. O. Varum, Francisco Veiga
Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 4
Swarna Bale, Mandip Singh, A. Shiva Shankar Reddy, Amit Khurana, Chandraiah Godugu
Lipid Nanoparticles for Nasal/Intranasal Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 3
S. Cunha, M. H. Amaral, J. M. Sousa Lobo, Ana C. Silva
Immunotoxicity of Therapeutic Antibodies and Nanoparticles
Critical Reviews™ in Immunology, Vol.40, 2020, issue 1
Nadire Özenver, Thomas Efferth
Inhalational Drug Delivery in Pulmonary Aspergillosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 3
Charan Singh, Amit K. Goyal, Ripandeep Kaur, Kamalinder K. Singh, Ranjot Kaur, Bhupinder Singh, Shahdeep Kaur